Roots Analysis has announced the addition of "Human Microbiome Market, 2019-2030

Roots Analysis has announced the addition of "Human Microbiome Market, 2019-2030" report to its list of offerings.
Spread the Word
Listed Under

* Research

* Health

* Cheraw - South Carolina - US

* Reports

CHERAW, S.C. - Sept. 17, 2020 - PRLog -- The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.

To order this 640+ page report, which features 235+ figures and 275+ tables, please visit this link

Key Market Insights

260 therapy candidates are currently in different phases of development

Nearly 25% of pipeline drugs are in the clinical phase of development, while the rest are in the preclinical / discovery stage. Interestingly, most of these drugs target digestive and gastrointestinal disorders (20%); this is followed by product candidates intended for treatment of oncological disorders (17%) and infectious diseases (13%).

Over 30 microbiome diagnostic tests are currently available / under development

Around 30% of the abovementioned tests have been commercialized, while the rest are under development. Of the total tests, notable examples of companies that launched a microbiome-based diagnostic solution include (in alphabetical order) ARTPred, Genetic Analysis, Goodgut, Invivo Healthcare, IS-diagnostics, Luxia Scientific and Varinos.

FMTs are the only commercially available microbiome therapy

This therapeutic product is presently indicated for the treatment of recurrent Clostridium difficile infections (rCDIs). Further, non-industry players (such as University of Alberta, The Second Hospital of Nanjing Medical University, University of California and Chinese University of Hong Kong) are making notable contributions in this arena, having been involved in ~200 clinical trials till August 2019.

51% growth in capital investments has been observed since 2015; around 70% investment has come from Venture Capital investors

It is worth noting that more than 80 investors have supported the R&D programs initiated by start-ups focused on microbiome-related products.  Well-funded start-ups have initiated product development programs, having invested significant time and effort to explore the applicability of microbiome therapeutics across various indications.

For additional details, please visit or email

You may also be interested in the following titles:

1.      Antibody Drug Conjugates Market (5th Edition), 2019-2030 (

2.      Gene Therapy Market (3rd Edition), 2019 - 2030

3.      Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

4.      Synthetic Lethality-based Drugs and Targets Market, 2019-2030


Gaurav Chaudhary

+1 (415) 800 3415

Roots Analysis
Location:Cheraw - South Carolina - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share